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The susceptibility of Saccharomyces cerevisiae JG436 multidrug transporter deletion mutant, Dpdr5, to seve-
ral antifungal agents was compared to that of JG436-derived JGCDR1 and JGCaMDR1 transformants, harbor-
ing the CDR1 and CaMDR1 genes, encoding the main drug-extruding membrane proteins of Candida albicans.
The JGCDR1 and JGCaMDR1 yeasts demonstrated markedly diminished susceptibility to the azole antifun-
gals, terbinafine and cycloheximide, while that to amphotericin B was unchanged. Surprisingly, JGCDR1 but
not JGCaMDR1 cells showed enhanced susceptibility to peptidic antifungals, rationally designed compounds
containing inhibitors of glucosamine-6-phosphate synthase. It was found that these antifungal oligopeptides,
as well as model oligopeptides built of proteinogenic amino acids, were not effluxed from JGCDR1 cells. More-
over, they were taken up by these cells at rates two to three times higher than by JG436. The tested oligopep-
tides were rapidly cleaved to constitutive amino acids by cytoplasmic peptidases. Studies on the mechanism of
the observed phenomenon suggested that an additive proton motive force generated by Cdr1p stimulated
uptake of oligopeptides into JGCDR1 cells, thus giving rise to the higher antifungal activity of FMDP [N3-(4-
methoxyfumaroyl)-L-2,3-diaminopropanoic acid]-peptides.
The phenomenon of multidrug resistance is considered to be
the major challenge for modern chemotherapy. Although bet-
ter recognized and characterized in the case of cancer and
bacterial cells, it is also becoming an emerging problem in
antifungal chemotherapy, thus making worse the already dif-
ficult situation resulting from an increasing number of im-
munocompromised patients, the appearance of new human
pathogenic fungi, and the very limited number of available
antifungal chemotherapeutic agents (11). The molecular
mechanism underlying the multidrug resistance is an overex-
pression of membrane proteins belonging to different classes of
energy-dependent efflux pumps. Most of these proteins are the
members of a family of ATP-binding cassette (ABC) transport-
ers. A number of them have been already identified in fungi,
including Cdr1p and Cdr2p in Candida albicans (30, 32) and
Pdr5p in Saccharomyces cerevisiae (2). Moreover, transporters
of another type, the major facilitator superfamily (MFS), have
been also detected, including a product of the CaMDR1 gene
in C. albicans (6). The substrate spectrum of fungal multidrug
transporters covers most of the drugs used in clinics for the
treatment of disseminated infections, including fluconazole
and itraconazole (1). On the other hand, the multidrug-resis-
tant fungi retain in most cases the susceptibility to membrane-
affecting agents: amphotericin B (31) and basic oligopeptides
(13). This is in agreement with a general rule assuming that the
“classical” substrate for drug-extruding pumps is a predomi-
nantly hydrophobic molecule, usually bearing a localized pos-
itive or negative charge, penetrating the cell membrane by free
diffusion (36). However, some intracellularly acting antifungal
compounds are transported into the cells by active transport
systems. This group includes a known drug, 5-fluorocytosine
(8), and several antifungal agents that have not reached clinics
so far, including peptidic compounds, containing FMDP [N3-
(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid], an inhibi-
tor of glucosamine-6-phosphate (GlcN-6-P) synthase (24). Any
data on the affinity of these compounds to multidrug efflux
pumps have not been reported yet.
We present here the results of our recent studies on anti-
fungal activity of FMDP-peptides against multidrug-resistant
and drug-sensitive yeasts.
MATERIALS AND METHODS
Antifungal agents and other chemicals. Cycloheximide was from Sigma, St.
Louis, Mo. Fluconazole and tioconazole were from Pfizer, Milano, Italy. Am-
photericin B was from Bristol-Myers Squibb, New York, N.Y., and terbinafine
was from Sandoz, Ltd., Basel, Switzerland. FMDP, Nva-FMDP, and Lys-Nva-
FMDP were synthesized by R. Andruszkiewicz, Technical University of Gdan´sk.
All other chemicals were from Sigma.
Yeast strains and growth conditions. S. cerevisiae ATCC 9763 cells were stored
on Sabouraud agar slants and propagated in Sabouraud liquid medium at 30°C
with shaking. S. cerevisiae JG436 (MATa pdr5::Tn5 leu2 met5 ura3-52 mak71
KRB1) was a kind gift from J. Golin, Catholic University of America, Washing-
ton, D.C. This strain was hypersensitive to cycloheximide and some other unre-
lated antifungal agents (20). JG436 was transformed with CaMDR1-carrying
plasmid pNC39 and CDR1-carrying plasmid pS12, which had a common vector
background of pYEUra3 (12, 30). The resulting JG436 transformants are des-
ignated as JGCaMDR1 and JGCDR1. The JG436 yeast cells were propagated in
a yeast nitrogen base-glucose (YNBG) minimal medium containing 0.67% YNB
without amino acids (Difco), 2% glucose, L-methionine at 20 mg ml21, L-leucine
at 40 mg ml21, and uracil at 30 mg ml21, while the transformant strains were
maintained in a similar medium but lacking uracil.
Antifungal susceptibility tests. MICs were determined by the serial twofold
dilution method in 96-well microtiter plates in the minimal YNBG medium
described above for the JG436 strain. The inoculum size was 104 cells ml21.
Plates were incubated for 24 h at 30°C. The MIC was defined as the lowest drug
concentration preventing visible growth. Each compound was tested at least
three times. Determination of the pH dependence of the MIC was performed in
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RPMI 1640 medium with glutamine, without sodium bicarbonate but containing
2% glucose, buffered with 0.165 M MOPS (morpholinepropanesulfonic acid),
with the pH adjusted to the appropriate level with 1 M HCl or 1 M NaOH (26).
The inoculum size, incubation conditions, and MIC definition were the same as
those described above.
Determination of peptide uptake rates. Yeast cells grown exponentially in
YNBG medium were harvested by centrifugation (3,000 3 g, 5 min), washed with
50 mM potassium phosphate buffer (pH 5.0 or 6.5), and suspended in the same
buffer containing 1% glucose to a final cell density corresponding to an A660 of
1.0. The cell suspension was incubated at 30°C. After 10 min, an oligopeptide
solution was added to give a final concentration of 100 mM. At that moment and
at 5-min intervals thereafter, 2-ml samples of the cell suspension were withdrawn
and immediately filtered through the Whatman GF/A filters, and the filtrates
were used to determine the residual peptide concentration. Then, 1-ml portions
of the filtrates were taken and combined with 1.25-ml aliquots of a solution
containing 4% Na2B4O7 z 10H2O and 0.8 mg of 2,4,6-trinitrobenzenesulfonate
(TNBS) ml21. The reaction was carried out at 37°C for 30 min. The A420 value
was measured, and the peptide concentration was read from the appropriate
standard curve. Data were plotted as nanomoles of oligopeptide taken up by 1
mg (dry weight) of cells versus time. The initial uptake velocities were deter-
mined from the slopes of the linear part of the curves, in the 0- to 10-min region.
TLC. Qualitative analysis of the spent medium used for the determination of
peptide uptake rate was performed by thin-layer chromatography (TLC). Small
aliquots of filtrates were applied to silica gel-coated aluminum sheets. Chromato-
grams were developed in two solvent systems: system A, n-butanol–acetic acid–
water (4:1:1), and system B, chloroform-ethanol (2:1). The amino acids and
peptides were visualized by ninhydrin staining and FMDP-containing com-
pounds by quenching of UV light.
Preparation of cell extract. Yeast cells from the overnight culture on YNBG
were harvested by centrifugation and washed with cold 25 mM potassium phos-
phate buffer (pH 6.5). Cells were then suspended in a minimal amount of the
buffer and disrupted with French press. The resulting suspension was centrifuged
(35,000 3 g, 4°C, 45 min), and the supernatant was used as a cell extract for the
determination of peptide cleavage rates.
Determination of peptide cleavage rates. The incubation mixtures, consisting
of 10 ml of a 200 mM peptide solution in 50 mM potassium phosphate buffer (pH
6.5) and 2 ml of appropriately diluted crude extract (final protein concentration,
0.1 to 0.5 mg ml21), were incubated at 30°C. At 5-min intervals, 2-ml aliquots
were withdrawn and heated at 100°C for 3 min. The resulting suspensions were
centrifuged to remove protein precipitates, and the concentration of free amino
acids in the supernatant was determined by the Cd-ninhydrin procedure (9).
Determination of initial velocity of proton efflux. The initial velocities of
proton extrusion by mutant yeast cells were determined according to the proce-
dure described previously (14). Briefly, yeast mutant cells grown in the YNBG
medium lacking uracil were harvested in the mid-exponential phase of growth,
washed twice with water, and suspended in fresh, unbuffered water at 108 cells
ml21. Cell suspensions were preincubated for 5 min at 30°C in a water-circulating
chamber with constant stirring. The incubation was continued, and the pH of the
cell suspensions was monitored with a PHM-62 pH meter (Radiometer, Copen-
hagen, Denmark). The release of protons was recorded for 5 min. The corre-
sponding amount of proton released was then calculated after we corrected for
the buffer capacity of the yeast suspension, as determined by the addition of a
known amount of 10 mM HCl solution.
Other methods. The protein concentration was measured by the Bradford
procedure (7), using bovine serum albumin as a standard. The activity of GlcN-
6-P synthase was assayed in cell extracts according to a previously published
method (18). One unit of specific activity was defined as an amount of enzyme
that catalyzed formation of 1 mmol of GlcN-6-P h21 mg of protein21.
RESULTS AND DISCUSSION
Genetically modified yeast mutant cells, JG436, lacking the
main yeast drug extruding pump Pdr5p and its transformants
containing C. albicans genes encoding Cdr1p and CaMdr1p
drug exporters, respectively, can serve as useful research tools
for studies on substrate specificity of candidal drug efflux sys-
tems. We used these transformants for the determination of
in vitro growth inhibitory activity of several antifungal agents.
The results of this experiment are shown in Table 1. As could
be expected, both JGCDR1 and JGCaMDR1 cells demon-
strated reduced susceptibility to a number of antifungals com-
pared to the parent JG436 strain, while the activity of the
membrane-active antifungal compound amphotericin B was
exactly the same against all types of mutant cells. On the other
hand, JGCDR1 yeast cells demonstrated enhanced suscepti-
bility to Nva-FMDP and Lys-Nva-FMDP, whereas JGCaMDR1
was unchanged compared to JG436. A similar phenomenon
was also observed for other FMDP-oligopeptides, containing
two to four amino acid residues (data not shown). The suscep-
tibility of JG436 cells to antifungal agents under study was the
same or slightly higher than that of the standard yeast strain
ATCC 9763. The MIC values for FMDP-peptides against yeast
transformants were two to four times lower, when the deter-
mination was made in YNBG medium containing L-glutamate
at 2 mg ml21, instead of ammonium sulfate as a nitrogen
source (data not shown). This difference probably reflects the
nitrogen catabolite repression of peptide transport systems,
which is well known and characterized in S. cerevisiae (5).
Moreover, it should be mentioned that FMDP-peptides are
generally much more active against human pathogenic fungi,
especially C. albicans (23, 24), than against baker’s yeast.
It was previously shown that FMDP-peptides are trans-
ported into C. albicans cells by peptide permeases and cleaved
intracellularly by peptidases, and the released FMDP inhibits
activity of the enzyme L-glutamine:D-fructose 6-phosphate
amidotransferase (EC 2.6.1.16, known as GlcN-6-P synthase)
(24). In consequence, the biosynthesis of the glucosamine-
containing cell wall macromolecules, chitin and mannoprotein,
is inhibited (24). It was also evidenced that the relative rates of
uptake of an oligopeptide antifungal agents determine their
anticandidal activity (22). Therefore, trying to find an expla-
nation for unusual susceptibility of JGCDR1 yeast to FMDP-
peptides, we determined the uptake rates of these compounds
and a few oligopeptides built exclusively of proteinogenic
amino acids by JG436 transformants cells. Determinations of
uptake rates of small molecules into microbial cells are usually
made using radiolabeled compounds. However, it is known
that in the case of oligopeptides this approach may result in
false results due to the efflux of degradation products contain-
ing radioisotopes (28). We used our own method based on the
colorimetric assay of yellow products of reaction between pep-
tides and TNBS (23). This approach is based upon the assump-
tion that a peptide is the only compound reacting with TNBS
that is present in the external medium. Therefore, our exper-
TABLE 1. Growth-inhibitory activity of several antifungal agents
against yeast mutants and yeast standard straina
Antifungal
agent
MICb (mg ml21) against strain:
JG436 JGCDR1 JGCaMDR1 ATCC 9763
Fluconazole 3.2 25 50 6.4
Tioconazole 0.1 1.6 1.6 0.1
Terbinafine 8 32 16 8
Amphotericin B 0.2 0.2 0.2 0.2
Cycloheximide 0.05 0.8 1.6 0.2
Nva-FMDP 25 3.2 25 25
Lys-Nva-FMDP 200 25 200 200
a MICs were determined by the microtiter serial twofold dilution method in
YNB medium containing 1% glucose. Inoculum size was 104 cells ml21. Plates
were incubated for 24 h at 30°C.
b MIC was defined as the lowest concentration of an antifungal agent prevent-
ing visible growth.
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iment was carried out in a phosphate-buffered glucose solu-
tion, and no amino group-containing compounds were added
except the tested oligopeptide. The examined peptides were
continuously taken up by all tested types of yeast mutants. The
uptake was linear for at least 15 to 20 min, and then its velocity
gradually decreased, thus reflecting the influence of decreasing
concentration of the oligopeptide in the medium. The initial
uptake velocities of several oligopeptides by JG436 and
JGCDR1 cells, determined from the slopes of the linear part of
the experimental curves, are demonstrated in Table 2. The
results show that all tested oligopeptides were taken up by
CDR1-expressing JGCDR1 cells at higher rates than by JG436
yeast lacking Cdr1p. On the other hand, the oligopeptide up-
take by both yeast transformants was faster at pH 5.0 than at
pH 6.5. This finding is consistent with the previous report on
properties of yeast oligopeptide transport systems (4). It is also
noteworthy that the differences between the uptake rates ex-
hibited by JGCDR1 and JG436 were in most cases larger at pH
6.5 than at pH 5.0. The initial velocities of oligopeptide uptake
by JGCaMDR1 cells were almost identical at both pH values
to those demonstrated by JG436.
FMDP was very slowly taken up by yeast mutants. The initial
velocities of its uptake were within the range of 0.1 to 0.3 nmol
min21 mg (dry weight)21.
The TLC analysis revealed that the tested oligopeptides were
the only ninhydrin-positive compounds present in the spent
media. No spots corresponding to the constitutive amino acids
were detected. We did not also detect any UV light-absorbing
compounds in the spent medium separated from cells treated
with Nva-FMDP or Lys-Nva-FMDP, except the FMDP-oligo-
peptides themselves. Nevertheless, some especially fast-absorbed
oligopeptides (e.g., His-Met or Leu-Leu-Leu) were completely
removed from the medium after 20 to 30 min, when no com-
pound reacting with TNBS could be detected any longer. The
same was true after 40 to 50 min for FMDP-peptides, which
were taken up at lower rates. Moreover, the shapes of all ex-
perimental curves obtained by us in uptake experiments were
similar, a result characteristic for the continuous inward trans-
port by permease, and not affected by any efflux phenomena.
We can therefore conclude that neither the tested oligopep-
tides nor their constitutive amino acids were effluxed from the
yeast JG436 and its CDR1 and CaMDR1 transformants.
It was previously shown that the effectiveness of anticandidal
action of FMDP-peptides is influenced by three factors: the
velocity of uptake, the rate of intracellular cleavage, and the
affinity for the intracellular target, with the first factor being
crucial for the overall activity (24). We therefore determined
the rates of cleavage of Nva-FMDP and Lys-Nva-FMDP by
peptidases present in cell extracts prepared from mutant yeast.
The results of this experiment shown in Table 3 clearly dem-
onstrate that the rates were practically the same, irrespectively
of the source of the cell extract used for determination. On
the other hand, the cleavage rates were much higher than the
corresponding uptake velocities shown in Table 2. The TLC
analysis of solutions containing FMDP-peptides (100 mM) in-
cubated at 30°C in the presence of crude extracts (protein
concentration, 1 mg ml21) confirmed a very quick release of
free amino acids. Spots corresponding to FMDP appeared as
quickly as within 45 to 60 s. One may doubt whether the results
of this in vitro experiment can be related to the intracellular
conditions. However, a very fast cleavage of different oligopep-
tides internalized by yeast cells was previously demonstrated
(4, 17), and a correlation between results obtained under in
vitro and in vivo conditions was also shown (25).
There was no difference in the specific activity of GlcN-6-P
synthase present in cell extracts prepared from yeast mutants
and the sensitivity of this enzyme to inhibition by FMDP. The
specific activity of the enzyme was 0.046 6 0.003 U, and the
50% inhibitory concentration for FMDP was 7.5 6 0.2 mM. It
is therefore clear that neither the rate of enzymatic hydrolysis
nor the interaction of FMDP with its intracellular target influ-
ence the growth-inhibitory activity of FMDP-peptides against
yeast mutants. This seems to be exclusively determined by the
inward transport rates. A similar conclusion was previously
drawn for the anticandidal activity of FMDP-peptides (23) and
some other peptidic antifungals (22).
Since we observed that the FMDP-peptide uptake rate was
pH dependent (Table 2), it seemed reasonable to establish the
pH dependence of the antiyeast activity of FMDP-peptides.
This was done by determining the MICs in buffered RPMI
media. The medium composition and conditions of this assay
were in compliance with recommendations of the National
TABLE 2. Initial velocities of oligopeptide uptake by yeast mutants
Peptide ExternalpH
Mean initial uptake ratea
(nmol min21 mg [dry wt]21) 6 SD by:
JG436 JGCDR1 JGCaMDR1
Nva-FMDP 5.0 1.81 6 0.22 3.03 6 0.33 1.75 6 0.14
6.5 0.94 6 0.16 1.82 6 0.22 0.91 6 0.15
Lys-Nva-FMDP 5.0 1.11 6 0.12 1.95 6 0.17 1.01 6 0.15
6.5 0.45 6 0.15 0.87 6 0.08 0.49 6 0.08
Leu-Met 5.0 4.87 6 0.28 5.84 6 0.42 4.66 6 0.48
6.5 3.20 6 0.31 4.15 6 0.38 3.12 6 0.28
His-Met 5.0 5.25 6 0.44 5.68 6 0.29 5.08 6 0.33
6.5 4.30 6 0.25 4.88 6 0.52 4.30 6 0.30
Met-Met-Met 5.0 2.81 6 0.11 3.64 6 0.32 2.62 6 0.22
6.5 1.17 6 0.09 1.94 6 0.16 1.31 6 0.11
Leu-Leu-Leu 5.0 3.25 6 0.06 5.02 6 0.44 3.22 6 0.40
6.5 1.85 6 0.30 4.45 6 0.32 1.91 6 0.21
(Ala)5 5.0 1.42 6 0.10 2.73 6 0.18 1.50 6 0.15
6.5 0.22 6 0.04 1.63 6 0.17 0.33 6 0.05
a Suspensions of yeast cells in 50 mM potassium phosphate buffer (pH 5.0 or
6.5) containing 1% glucose (final cell density corresponding to A660 5 0.8 4 1.0)
were incubated at 30°C. Samples (2 ml) of the cell suspensions were withdrawn
immediately after the addition of an oligopeptide (100 mM) and at 5-min inter-
vals thereafter. Cells were removed by filtration, and the concentrations of the
oligopeptides remaining in the filtrates were determined by the TNBS method.
Values are the means of five determinations 6 the standard deviation.
TABLE 3. Rates of cleavage of FMDP-peptides by peptidases
present in crude extracts prepared from yeast mutant cells
FMDP-peptide
Mean cleavage ratea
(nmol min21 mg of protein21) 6 SD
JG436 JGCDR1 JGCaMDR1
Nva-FMDP 13.7 6 2.2 14.4 6 2.8 15.2 6 0.9
Lys-Nva-FMDP 18.1 6 1.6 16.2 6 1.3 18.0 6 2.0
a Mixtures containing 200 mM peptide solution in 50 mM potassium phosphate
buffer (pH 6.5) and appropriately diluted crude extract, prepared from exponen-
tially growing yeast cells, were incubated at 30°C. Samples of incubation mixtures
were collected at 5-min intervals and deproteinized, and the concentration of
free amino acids in the supernatant left after removal of protein precipitate was
determined by the Cd-ninhydrin procedure. Values are the means of three
independent determinations 6 the standard deviation.
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Committee for Clinical Laboratory Standards (26). The results
(Fig. 1) clearly demonstrate that the growth-inhibitory activity
of FMDP-peptides against both JG436 and JGCDR1 cells was
strongly enhanced in acidic media. A similar phenomenon was
also observed for JGCaMDR1 (data not shown).
Oligopeptides containing two to six amino acid residues are
transported into C. albicans and S. cerevisiae cells by energy-
dependent permeases. The extensive studies on peptide trans-
port system in C. albicans led to the identification and char-
acterization of at least two components: the di- and
tripeptide permease and the oligopeptide permease trans-
porting tri-, tetra-, penta-, and hexapeptides (3, 5, 21, 23). In
S. cerevisiae, a product of the PTR2 gene was unequivocally
identified as a di- and tripeptide permease, with very low af-
finity for longer oligopeptides (29). The molecular mechanism
of peptide translocation by Ptr2p is not known, but the pH
dependence of its activity, with a pH optimum of 5.5 (16) and
a sequence homology to other members of the PTR family of
transport proteins (35), indicate that this permease acts as an
H1-oligopeptide symporter. We were able to confirm this as-
sumption by demonstrating the strong inhibitory effect of the
known proton shuttle, carbonyl cyanide m-chlorophenylhydra-
zone (CCCP) on peptide uptake by yeast mutants and their
transformants (Fig. 2). The presence of this agent (100 mM)
practically completely stopped the oligopeptide uptake.
The only difference between JG436 and JGCDR1 cells is the
presence of the Cdr1p efflux pump in the latter. It is therefore
clear that the unusually high susceptibility of the JGCDR1
cells to FMDP-peptides should be a consequence of a possible
activity of this ABC transporter. One of the theoretical sug-
gestions for the mechanism of this phenomenon could be the
action of Cdr1p as an additional oligopeptide permease. This
idea seemed very unlikely since this protein is known to act
exclusively as an export pump, but experimental verification
was required. Such evidence was provided by the results of the
experiment in which the growth-inhibitory activity of FMDP-
peptides and cycloheximide was determined in the presence of
the calcium channel blocker, verapamil, which is known to be
a very good substrate for P-glycoprotein (37). The data pre-
sented in Table 4 show that the presence of this compound
strongly increases the susceptibility of JGCDR1 cells to the
action of cycloheximide and has no effect on susceptibility of
JG436 yeast. This result was expected since Cdr1p blocked by
verapamil was supposed to be switched off as a potential way of
cycloheximide efflux. On the other hand, verapamil had no
FIG. 1. pH dependence of antifungal in vitro activity of Nva-FMDP
(A) and Lys-Nva-FMDP (B) against JG436 and JGCRD1 cells. MICs
were determined by microtiter serial twofold dilution method in RPMI
medium buffered with 0.165 M MOPS. Inoculum size was 104 cells
ml21. Plates were incubated for 24 h at 30°C, and the results were read
visually.
FIG. 2. Influence of CCCP and verapamil on oligopeptide uptake
by JG436 (A) and JGCDR1 (B) cells. The initial rates of oligopeptide
uptake were determined in 50 mM phosphate buffer (pH 6.5) contain-
ing 1% glucose. Other details were the same as those described in the
legend to Table 2. Each bar represents the mean of three independent
determinations 6 the standard deviation.
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effect on the antifungal activity of FMDP-peptides against
JG436 and JGCDR1. No effect was also observed in the case
of JGCaMDR1 cells (data not shown). We did not note any
substantial influence of verapamil on oligopeptide uptake to
yeast transformants, except the very slight stimulation of their
uptake in the case of JGCDR1 cells (Fig. 2). Any competition
between FMDP-peptides and verapamil for Cdr1p can there-
fore be excluded.
Another possibility which may be taken into account as a
probable mechanism of observed supersensitivity is the cre-
ation of an additional driving force for peptide transport due to
the presence of Cdr1p. This protein is a C. albicans homologue
of the human Mdr1p efflux pump (30), well known as a P-
glycoprotein. This is therefore likely that the substrate speci-
ficity of both drug exporters should be similar. In this respect,
it is worth mentioning that P-glycoprotein is known to export
some peptides. However, we must stress that this opinion con-
cerns some very specific compounds, e.g., ionophoric peptides
such as gramicidin and valinomycin or hydrophobic cyclic and
linear modified peptides or peptide derivatives such as NAc-
L-leucyl-L-leucyl-L-methioninal, pepstatin A, cyclosporin A, or
leupeptin (33, 34). Ionophoric peptides were also shown to be
the substrates for yeast Pdr5p (19). Small, unmodified linear
peptides have never been studied in this respect. On the other
hand, Fritz et al. reported quite recently that human Mdr1p
(P-glycoprotein) overexpressed in S. cerevisiae, acts at low ex-
ternal pH as a H1 efflux and Cl2 influx pump, whereas at a pH
of .8 it promotes ion translocation in the opposite directions
(10). It was even suggested that biophysical perturbations due
to abnormal ion transport might be a natural activity of this
protein and the multidrug resistance phenotype could be fully
explained by changes in the membrane potential and proton
gradient generated by human Mdr1p (15). The structural ho-
mology between Cdr1p and human P-glycoprotein allows us
to put forward a working hypothesis that Cdr1p expressed in
S. cerevisiae may also create an additional proton motive force.
This should in turn drive the oligopeptide transport by an
H1-dependent peptide permease and thus enhance the anti-
fungal activity of FMDP-peptides. In order to verify this hy-
pothesis we determined the initial velocities of proton efflux
from yeast mutant cells suspended in unbuffered water. The
results of this experiment (Fig. 3) clearly demonstrate that the
JGCDR1 cells effluxed almost three times more protons per
minute than did the JG436 and JGCaMDR1 cells. Our hy-
pothesis has been additionally strengthened by an identical
growth-inhibitory activity of FMDP-peptides against JG436
and JGCaMDR1 and similar uptake rates of oligopeptides
by both transformant cells. The drug efflux pump CaMdr1p
present in JGCaMDR1 belongs to the MFS of drug exporters.
The MFS proteins act as H1-substrate antiporters (27), so that
their action cannot create any additional proton motive force.
Since, on the other hand, our data show that CaMdr1p ex-
trudes neither FMDP-peptides nor their constitutive amino
acids, it is not surprising that the presence of this pump has no
effect on antifungal activity of FMDP-peptides.
To our best knowledge, FMDP-peptides are the first re-
ported example of antimicrobial agents that are more active
against multidrug-resistant cells. Although the hypothesis on
the molecular mechanism of this supersensitivity needs further
experimental evidence, the phenomenon itself seems to open
the new possibilities of overcoming the multidrug resistance
problem. In our opinion this could be done by the application
of structural mimics of natural metabolites: peptides, amino
acids, or sugars as antimicrobial agents. Such compounds are
transported unidirectionally into the cells by respective per-
meases and are less likely to be extruded by drug efflux pumps
than xenobiotics. Moreover, our results presented above indi-
cate that, at least in some cases, i.e., agents transported into
the cells by H1-substrate symporters, there is a chance for the
paradoxically enhanced susceptibility of potentially “resistant”
cells. Work is in progress in our laboratory to verify this hy-
pothesis.
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